5:46 PM
 | 
Oct 28, 2013
 |  BC Extra  |  Clinical News

J&J looking to add structural damage data to Stelara label

Johnson & Johnson (NYSE:JNJ) presented data on Monday at the American College of Rheumatology meeting in San Diego showing subcutaneous Stelara ustekinumab met the secondary endpoint of greater inhibition of structural damage at week 24 vs. placebo in a pre-specified analysis of the Phase III PSUMMIT I...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >